A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 30 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Durvalumab (Primary) ; Neoantigen DNA vaccine AstraZeneca/Washington University School of Medicine (Primary)
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Adverse reactions

12 Dec 2023 Status changed from active, no longer recruiting to discontinued.
21 Apr 2023 Planned End Date changed from 25 Feb 2023 to 25 Aug 2023.
21 Dec 2022 Planned End Date changed from 23 Aug 2023 to 25 Feb 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com